Abstract
B-cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia. Deregulation of the T-cell leukemia/lymphoma 1 (TCL1) oncogene in mouse B cells causes a CD5-positive leukemia similar to aggressive human B-CLLs. We recently reported that levels of TCL1 expression in B-CLL are regulated by miR-29 and miR-181 that target 3′ UTR of TCL1. To determine whether treatment with microRNAs targeting TCL1 can inhibit B-CLL in mice, we generated TCL1 transgenic mice using a construct containing the 3′ and 5′ UTRs of TCL1 under B-cell-specific Eμ promoter (Eμ-TCL1FL). At the age of 16–20 months, these mice showed B-CLL-like disease. Immunophenotyping revealed accumulation of CD5+CD23+B220+ population in spleens and lymph nodes. Our results show that CD5+CD23+ B-cell populations from Eμ-TCL1FL mice actively proliferate and show significantly increased levels of phospho-Akt. Eμ-TCL1FL mice showed immunological abnormalities similar to human B-CLL, including hypoimmunoglobulinemia, abnormal levels of cytokines and impaired immune response. These findings revealed biochemical and immunological similarities between Tcl1-driven B-CLL in mice and human B-CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sgambati M, Linet M, Devesa S . Chronic lymphocytic leukemia, epidemiological, familial, and genetic aspects. In: Cheson B (ed.) Chronic Lymphocytic Leukemias, 2nd edn., revised and expanded. Marcel Dekker, Inc.: New York, 2001, pp 33–62.
Bullrich F, Croce C In: Cheson B (ed.) Molecular Biology of Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemias, 2nd edn., revised and expanded. Marcel Dekker, Inc.: New York, 2001, pp 9–32.
Chiorazzi N . Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20: 399–413.
Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755–764.
Sieklucka M, Pozarowski P, Bojarska-Junak A, Hus I, Dmoszynska A, Rolinski J . Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol Rep 2008; 19: 1611–1620.
Caligaris-Cappio F, Hamblin TJ . B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17: 399–408.
Bojarska-Junak A, Rolinski J, Wasik-Szczepaneko E, Kaluzny Z, Dmoszynska A . Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia. Haematologica 2002; 87: 490–499.
Pekarsky Y, Zanesi N, Aqeilan R, Croce CM . Tcl1 as a model for lymphomagenesis. Hematol Oncol Clin North Am 2004; 18: 863–879.
Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530–12534.
Teitell MA . The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer 2005; 5: 640–648.
Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955–6960.
Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590–11593.
Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006; 20: 280–285.
Monaghan SA, Peterson LC, James C, Marszalek L, Khoong A, Bachta DJ et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2003; 56: 30–42.
DiRaimondo F, Albitar M, Huh Y, O’Brien S, Montillo M, Tedeschi A et al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer 2002; 94: 1721–1730.
Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J . Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008; 111: 1594–1602.
Cardinaud B, Moreilhon C, Marcet B, Robbe-Sermesant K, LeBrigand K, Mari B et al. miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia? Leukemia 2009; 23: 2174–2177.
Palamarchuk A, Zanesi N, Aqeilan RI, Aqeilan RI, Croce CM, Pekarsky Y . Tal1 transgenic expression reveals absence of B lymphocytes. Cancer Res 2006; 66: 6014–6017.
Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S et al. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 2000; 97: 3028–3033.
Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755–11760.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.
Acknowledgements
The research was supported by an ACS Research Scholar grant (Y Pekarsky).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Efanov, A., Zanesi, N., Nazaryan, N. et al. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 24, 970–975 (2010). https://doi.org/10.1038/leu.2010.46
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.46
Keywords
This article is cited by
-
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
Journal of Hematology & Oncology (2021)
-
Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model
Oncogene (2017)
-
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
Cell Death & Disease (2016)
-
The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL
Leukemia (2015)
-
Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function
Leukemia (2013)